- For US Eye Care
Professionals - Important Safety
Information - Full Prescribing
Information - Patient
Information - Medical
Information - Visit
Patient Site - REQUEST A REP
- SIGN UP
ELIGIBLE COMMERCIAL Patients may pay as little as
Need to enroll your patient for a copay card?
Help your patients get started with the Xiidra My Saviings Program by having them register for a copay card or activate an existing card at xiidra.blsavingscard.com
Additional questions about cost and affordability?
For more on helping patients start and stay on Xiidra and information on the Xiidra My Saviings Program for eligible commercial patients, please call the copay program support line at 1-877-4XiiDRA (1-877-494-4372)
We've got you and your patients covered
Commercial
~90% of eligible commercial patients paid $0 with the Xiidra copay card†‡
Medicare Part D
Xiidra has Medicare coverage for more patients than Restasis®, Cequa®, Tryptyr®, Tyrvaya®, and Vevye®*§
There are additional ways to help patients save
BlinkRx assists with prior authorizations and more, offering a seamless experience for your patients
Prior Authorization Support
BlinkRx services provide prior authorization support for Xiidra prescriptions, should your patients’ insurance require it
Low Price
BlinkRx works with your eligible commercially insured patients’ insurance and applies available savings to their Xiidra prescription, with no co-pay card needed
Free and Fast Delivery
BlinkRx delivers Xiidra prescriptions for free from one of their licensed network pharmacies around the country
Simple Patient Experience
BlinkRx will send patients a text with the lowest available price so that they can immediately purchase their Xiidra prescription online or over the phone
Ample Stocking
BlinkRx services the entire country, making Xiidra accessible for all patients
Dedicated Customer Support
BlinkRx has a team of pharmacists and technicians who are available to support you, your team, and your patients from onboarding to adherence
Want to learn more about BlinkRx?
Find a helpful guide and additional downloadable resources
Is your patient experiencing financial hardship?
For patients who have limited or no prescription coverage, contact the Bausch + Lomb Patient Assistance Program at 855-770-0424 or visit www.patientassistance.bausch.com. Patients who are eligible may receive their medication for free
GET STARTED WITH BLINKRx
Being proactive in the prior authorization process may help improve your patients’ success with Xiidra
Help Patients Start and Stay on Xiidra
Send patients home with the materials they need for a smooth onboarding process
*Based on MMIT data from January 2026.
†Based on ConnectiveRx data from August 2024.
‡Terms and conditions apply. For the first 30-, 60-, or 90-day prescription. Subject to benefit limitations. Visit Xiidra.com for complete terms and conditions.
§Formulary coverage comparisons do not imply comparable efficacy, safety, or dosing.
Indication and important safety information
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
- Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
- In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
- To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
- Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
- Safety and efficacy in pediatric patients below the age of 17 years have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for Xiidra.
Indication and important safety information
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
- Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
- In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced